Ainos Inc. (NASDAQ:AIMD) shares climbed 5% in premarket trading on Monday after the company unveiled plans to expand its smell-based AI technology into healthcare infrastructure.
The rollout will target environmental monitoring and safety applications across hospital power systems, HVAC networks, chemical handling areas, and clinical laboratory environments, including MRI facilities. This marks a strategic shift beyond Ainos’ traditional focus on semiconductor and industrial use cases.
At the core of the offering is the company’s AI Nose platform, which combines sensor arrays with proprietary algorithms to detect scents and translate analog signals into structured data via its Smell ID system. The platform also incorporates a Smell Language Model designed to analyze and classify scent patterns over time.
A third-party report from VASRO GmbH noted that the technology enables scent signals to be converted into machine-readable data for environmental monitoring. The report highlighted 2026 as a key scaling year for Ainos as it moves toward broader deployment and revenue generation across multiple industries.
“We are building Smell AI-powered by AI Nose-as a new layer of AI infrastructure that enables machines to sense, learn, and predict invisible scent signals,” said Eddy Tsai, Chairman, President and CEO.
The company said it plans to deploy the technology using a service-based model for its scent detection solutions.